drug_type
RELEVANT_DRUG
intervention_type
Gene therapy (viral vector)
drug_description
An intravenously administered, third-generation self-inactivating lentiviral gene therapy vector that transduces autologous T cells in vivo to express an anti-BCMA chimeric antigen receptor, resulting in in vivo–generated CAR-T cells that target BCMA (TNFRSF17) on myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lentiviral Vectors
drug_category
GENE THERAPY
drug_class
Gene therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
An intravenously delivered, self-inactivating third-generation lentiviral vector that transduces patients' autologous T cells in vivo to express an anti-BCMA chimeric antigen receptor; the resultant in vivo–generated CAR-T cells recognize BCMA (TNFRSF17) on myeloma cells and induce T-cell activation and cytotoxic killing.
drug_name
ESO-T01
nct_id_drug_ref
NCT06691685